Multiple View Ultrasound Aids Breast Lesion Characterization and Biopsy Needle Tracking

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 1
Volume 9
Issue 1

CHICAGO-A new ultrasound technology that amasses as much as nine times more information than conventional ultrasound provides greater detail in characterizing breast lesions and also allows real-time tracking of the entire path of the breast biopsy needle, Jacques Souquet, PhD, senior vice president and chief technology officer at ATL Ultrasound (Bothell, Washington), said in an interview with ONI.

CHICAGO—A new ultrasound technology that amasses as much as nine times more information than conventional ultrasound provides greater detail in characterizing breast lesions and also allows real-time tracking of the entire path of the breast biopsy needle, Jacques Souquet, PhD, senior vice president and chief technology officer at ATL Ultrasound (Bothell, Washington), said in an interview with ONI.

The new device, called SonoCT Real-Time Compound Imaging, was introduced to the US market at the 1999 annual meeting of the Radiological Society of North America (RSNA).

The SonoCT gathers images from several viewing angles and then combines them into a single image in real time, much like other compound imaging modalities such as computed tomography and magnetic resonance imaging.

Because SonoCT combines multiple looks at the same organ or tissue through various angles, it can reduce noise and artifacts, such as shadowing and refraction, that degrade conventional real-time ultrasound images, Dr. Souquet said. It reduces speckle and clutter, which increase noise and decrease image contrast, and it keeps on capturing signals even when echo interfaces do not occur at a 90-degree angle, he noted. These advantages improve imaging of normal and malignant breast tissue.

Because conventional ultrasound looks at the curvilinear breast from a single vantage point, it may miss important aspects of breast anatomy, such as microcalcifications, Dr. Souquet said. Conventional ultrasound does not provide clear delineation of lesion borders or the content of lesions, he added.

“With conventional ultrasound, we know there is a mass in the breast because it casts a shadow, but we can just barely see the border of the lesion. There also is so much noise, it is difficult to characterize the kind of mass you’re looking at,” Dr. Souquet said. “By having the capability of looking at the same pathology from various directions, SonoCT provides a continuous, well-delineated border of pathologies and more detail about the structures within a mass.”

SonoCT improves the recognition of microlobules or spicules along the margin of a breast lesion, which signal invasive carcinoma, for example, he noted.

The SonoCT compounding technology collects images from actual structures but suppresses those from random echoes or artifacts, helping to more clearly depict fibroadenomas with their smooth, well-defined margins and homogeneous internal echoes (see Figure 1).

SonoCT also enhances localization of the biopsy needle during breast tissue sampling (see Figure 2). “With conventional ultrasound, you can see the start of the insertion of the biopsy needle in a breast lesion, but then the signal is lost. With SonoCT, we interrogate the fields through various cycles and provide better visualization of the needle going all the way through the nodule during biopsy,” Dr. Souquet said.

The SonoCT Real-Time Compound Imaging technology can be added to ATL’s HDI 5000 system as an upgrade for imaging not only breast tissue but also musculoskeletal soft tissue, the scrotum, thyroid, and peripheral vasculature, Dr. Souquet said.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.